TROPION-Breast01: Dato-DXd in Metastatic HR+/HER2- Breast Cancer

Opinion
Video

Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content